Terry Rosen is currently the CEO of Flexus Biosciences. He has been leading successful organizations in the biotechnology and pharmaceutical industries for almost 30 years. Most recently, he served as Vice President, Therapeutic Discovery at Amgen and as the site head for Amgen South San Francisco, having joined Amgen with the acquisition of Tularik in 2004. Prior to joining Amgen, Terry held several executive positions at Tularik, including Executive Vice President, Operations, Vice President, Research Operations, and Vice President, Medicinal Chemistry. He has also held scientific and management positions at Pfizer and Abbott Laboratories. In addition to being on the BayBio Board, Terry serves as a member of the University of Michigan (UM) Undergraduate Research Opportunity Program Leadership Committee, the University of California, Berkeley College of Chemistry Advisory Board, the UM Life Sciences Institute Leadership Council and the Silicon Valley Leadership Group. Terry has a B.S. degree in Chemistry from the University of Michigan and a Ph.D. in Organic Chemistry from the University of California, Berkeley. He holds numerous patents and has published extensively in the areas of medicinal and synthetic organic chemistry.